# A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

> **NCT07102095** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Hepatic Insufficiency
- Liver Diseases
- Pharmacokinetics
- Drug Metabolism

## Interventions

- **DRUG:** Sevabertinib

## Key facts

- **NCT ID:** NCT07102095
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-24
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102095, "A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07102095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*